{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:40:56Z","timestamp":1793839256849,"version":"4.6.1"},"reference-count":27,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,7,5]],"date-time":"2010-07-05T00:00:00Z","timestamp":1278288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:p>The National Health Service (NHS) should reward innovation it values. This will enable the NHS and the United Kingdom (UK) economy to benefit and impact positively on the Research and Development (R&amp;D) decision making of companies. The National Institute for Health and Clinical Excellence (NICE) currently seeks to do this on behalf of the NHS. Yet the Office of Fair Trading proposals for Value Based Pricing add price setting powers \u2013 initially for the Department of Health (DH) and then for NICE. This introduces an additional substantial uncertainty that will impact on R&amp;D and, conditional on R&amp;D proceeding, on launch (or not) in the UK. Instead of adding to uncertainty the institutional arrangements for assessing value should seek to be predictable and science based, building on NICE's current arrangements. The real challenge is to increase understanding of the underlying cost\u2010effectiveness of the technology itself by collecting evidence alongside use. The 2009 Pharmaceutical Price Regulation Scheme sought to help do this with Flexible Pricing (FP) and Patient Access Schemes (PASs). The PASs to date have increased access to medicines, but no schemes proposed to date have yet helped to tackle outcomes uncertainty. The 2010 Innovation Pass can also be seen as a form of \u2018coverage with evidence development.\u2019 The NHS is understandably concerned about the costs of running such evidence collection schemes. Enabling the NHS to deliver on such schemes will impact favourably on R&amp;D decisions. Increasing the uncertainty in the UK NHS market through government price setting will reduce incentives for R&amp;D and for early UK launch.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2010.03740.x","type":"journal-article","created":{"date-parts":[[2010,7,6]],"date-time":"2010-07-06T23:57:47Z","timestamp":1278460667000},"page":"360-366","source":"Crossref","is-referenced-by-count":48,"title":["Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?"],"prefix":"10.1111","volume":"70","author":[{"given":"Adrian","family":"Towse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,16]]},"reference":[{"key":"e_1_2_8_2_2","unstructured":"The OFT Report.The pharmaceutical price regulation scheme. Office of Fair Trading.2007. Available athttp:\/\/www.oft.gov.uk\/news\/press\/2007\/29\u201007(last accessed 27 July 2010)."},{"key":"e_1_2_8_3_2","unstructured":"KeyworthT YarrowG.Impact assessment review of the Office of Fair Trading's market study of the pharmaceutical price regulation. Scheme Regulatory Policy Institute.2007. Available athttp:\/\/www.rpieurope.org\/Research\/PPRS%20Impact%20Assessment%20Review%20Web.pdf(last accessed 27 July 2010)."},{"key":"e_1_2_8_4_2","unstructured":"Life Sciences Blueprint.A statement from the Office for Life Sciences. HM Government.2009. Available athttp:\/\/www.dius.gov.uk\/~\/media\/publications\/O\/ols\u2010blueprint(last accessed 5 February 2010)."},{"key":"e_1_2_8_5_2","unstructured":"OLS.Life sciences 2010. Delivering the blueprint. Office for Life Sciences.2010. Available athttp:\/\/www.bis.gov.uk\/policies\/innovation\/business\u2010support\/ols(last accessed 27 July 2010)."},{"key":"e_1_2_8_6_2","unstructured":"OLS BIS Economics Paper No2.Life sciences in the UK\u2010economic analysis and evidence for \u2018life sciences 2010: delivering the blueprint\u2019.2010. Available athttp:\/\/www.berr.gov.uk\/publications\/economicsstatistics\/economicsdirectorate\/page14636.html(last accessed 27 July 2010)."},{"key":"e_1_2_8_7_2","unstructured":"SussexJ GarauM.Estimating pharmaceutical companies' value to the national economy: case study of the British Pharma Group. OHE Briefing. Office of Health Economics 2007."},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03256161"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b5493"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03589.x"},{"key":"e_1_2_8_11_2","volume-title":"Deliberative Processes in Decisions about Health Care Technologies","author":"Culyer A","year":"2009"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1249"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39434.500185.25"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1263"},{"key":"e_1_2_8_15_2","unstructured":"NICE.Scientific advice consultancy service. Available athttp:\/\/www.nice.org.uk\/aboutnice\/scientificadvice\/AboutScientificAdvice.jsp(last accessed 27 July 2010)."},{"key":"e_1_2_8_16_2","unstructured":"DLTR.Multi\u2010criteria analysis manual.2000. Available athttp:\/\/iatools.jrc.ec.europa.eu\/public\/IQTool\/MCA\/DTLR_MCA_manual.pdf(last accessed 27 July 2010)."},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03569.x"},{"key":"e_1_2_8_18_2","unstructured":"Department of Health and Ageing and Medicines Australia.Activity indicators for the pharmaceutical benefits scheme. Second report: 2004 to 2008.2009. Available athttp:\/\/medicinesaustralia.com.au\/pages\/page222.asp(last accessed 10 June 2010)."},{"key":"e_1_2_8_19_2","unstructured":"Department of Health.The 2009 pharmaceutical price regulation scheme.2008. Available athttp:\/\/www.dh.gov.uk\/dr_consum_dh\/groups\/dh_digitalassets\/documents\/digitalasset\/dh_098498.pdf(last accessed 28 July 2010)."},{"key":"e_1_2_8_20_2","unstructured":"Department for Business Innovation and Skills.Final government response to recommendations aimed at government contained in the OFT report \u2018the pharmaceutical price regulation scheme\u2019.2009. Available athttp:\/\/www.berr.gov.uk\/files\/file51657.pdf(last accessed 28 July 2010)."},{"key":"e_1_2_8_21_2","unstructured":"Department of Health.Pharmaceutical price regulation scheme: tenth report to parliament.2009. Available athttp:\/\/www.dh.gov.uk\/dr_consum_dh\/groups\/dh_digitalassets\/@dh\/@en\/@ps\/@sta\/@perf\/documents\/digitalasset\/dh_111291.pdf(last accessed 28 July 2010)."},{"key":"e_1_2_8_22_2","unstructured":"MossL.New cancer drugs on NHS after price deal. The Scotsman.2009. Available athttp:\/\/news.scotsman.com\/cancerresearch\/New\u2010cancer\u2010drugs\u2010on\u2010NHS.5808768.jp(last accessed 28 July 2010)."},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.2165\/11314080-000000000-00000"},{"key":"e_1_2_8_24_2","unstructured":"ThomsonD.Position statement on \u2018risk sharing\u2019 schemes in oncology. Endorsed by BOPA (British Oncology Pharmacy Association).2007."},{"key":"e_1_2_8_25_2","unstructured":"WilliamsonS.A report into the uptake of patient access schemes in the NHS. Cancer Network Pharmacist Forum.2009. Available athttp:\/\/www.bopawebsite.org\/tiki\u2010download_file.php?fileId=626(last accessed 28 July 2010)."},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b4677"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c1786"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.15"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2010.03740.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2010.03740.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T19:04:54Z","timestamp":1694545494000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2010.03740.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,16]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1111\/j.1365-2125.2010.03740.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03740.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,16]]}}}